Will Thompson (@will-thompson96.bsky.social)

Big news for #TPD field, ARV-471 vs fulvestrant for ER degradation. I'll be interested to see PROTACs pitted against inhibitors rather than existing degraders next

loading . . .

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial | Arvinas – VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – V... https://ir.arvinas.com/news-releases/news-release-details/arvinas-and-pfizer-announce-positive-topline-results-phase-3